Skip to contentA
Acro Biomedical Co., Ltd.
A
ACBMAcro Biomedical Co., Ltd. Q2 2024 · 10-Q
Revenue$0.00$0.00— vs Q2 2023 Net Income-$10.14K-$10.14KN/M vs Q2 2023 EPS Diluted$0.00$0.00N/M vs Q2 2023 Operating Income-$9,086N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acro Biomedical Co., Ltd. · CIK 1622996 · Engraved from SEC EDGAR
derived
ended Jun 30, 2024 · filed Jul 23, 2025 · 388 d after period end